Vertero Therapeutics
PrivateLast Round
Series D
Oct 21, 2025
Total Funding Raised
$111.84M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Vertero Therapeutics operates in Healthcare & Life Sciences and is based in Woburn, Massachusetts. Its latest recorded funding round was a Series D round in October 2025.
Vertero Therapeutics is a biotechnology company that develops oral small-molecule therapeutics targeting peripheral nervous system drivers of neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vertero Therapeutics Comparables
Compare Vertero Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Piton Therapeutics | 86% | |
| Enterin | 82% | |
| Kallyope | 80% |
For institutional investors. Book with your work email.
Vertero Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Oct 21, 2025 | ||||
| Grant | Jun 20, 2023 | ||||
| Series C | Oct 13, 2021 | ||||
| Grant | Jul 28, 2020 | ||||
| Series B Extension | Jun 20, 2019 | ||||
Series B | Feb 27, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vertero Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OneVentures | Series D, Series C |
| Domain Associates | Series B, Series C, Series D, Series A |
| Kairos Ventures | Series A |
| Taiho Ventures | Series C, Series D, Series B Extension |
| Kairos Ventures | Series A |
| Corundum Systems Biology | Series C |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 1556% MoM.
- Oct 21, 2025
$20M round led by OneVentures and Seventure Partners.
For institutional investors. Book with your work email.
Vertero Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vertero Therapeutics's valuation, stock price, and market status.
Is Vertero Therapeutics a public or private company?
Vertero Therapeutics is a private company.
What is the current stock price of Vertero Therapeutics?
Vertero Therapeutics is a private company, so its shares have no public market price. Caplight tracks Vertero Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vertero Therapeutics worth (valuation)?
Valuation information for Vertero Therapeutics is not publicly available.
Can I buy Vertero Therapeutics stock?
Vertero Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vertero Therapeutics's last funding round?
Vertero Therapeutics's most recent funding round was Series D on October 21, 2025.
Who are the main investors in Vertero Therapeutics?
Key investors in Vertero Therapeutics include OneVentures, Domain Associates, Taiho Ventures, Longwood Fund, Seventure Partners.
Will Vertero Therapeutics IPO soon?
No public IPO plans have been announced for Vertero Therapeutics.
How can I track Vertero Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Vertero Therapeutics's shares on secondary markets.